Answers are grounded in this paper and cite their sources.
Erythrina variegata L. has long been used in traditional medicine; however, compound-specific enzyme inhibitory data for constituents of E. variegata remain limited. In present study, the phytochemical investigation of the stems of E. variegata yielded two known isoflavonoids, erythribyssin H (1) and eryvarin R (2), which were evaluated for their in vitro inhibitory activities against protein tyrosine phosphatase 1B (PTP1B) and α-glucosidase. Compounds 1 and 2 exhibited inhibitory activity against PTP1B with IC50 values of 4.12 ± 0.99 and 4.36 ± 0.74 µM, respectively. In the α-glucosidase assay, compounds 1 and 2 showed IC50 values of 96.33 ± 0.29 and 101.09 ± 0.87 µM, respectively. Exploratory molecular docking was performed to examine possible interactions with the selected enzyme structures, while absorption, distribution, metabolism, excretion and toxicity (ADMET) predictions provided preliminary estimates of physico-chemical, pharmacokinetic and toxicity-related properties. These findings provide compound-specific in vitro evidence of enzyme inhibition by two known constituents of E. variegata.
No takes yet. Share an insight, caveat, or question.
Vy et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: